Five‑year follow‑up of OPTIC: long‑term efficacy, safety, and mutation analyses of ponatinib in chronic‑phase chronic myeloid leukemia from a randomized phase 2 trial
Patients treated with the 45‑mg‑to‑15‑mg response‑based regimen achieved the highest rates of molecular response.
This finding supports that a response‑based dosing strategy with ponatinib can maintain durable molecular remissions while reducing long‑term exposure and associated toxicity in patients with resistant chronic‑phase chronic myeloid leukemia.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia